Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy

研究成果: ジャーナルへの寄稿小調査

59 引用 (Scopus)

抄録

The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.

元の言語英語
ページ(範囲)309-315
ページ数7
ジャーナルFEBS Journal
277
発行部数2
DOI
出版物ステータス出版済み - 1 1 2010

Fingerprint

Epidermal Growth Factor Receptor
Tumors
Neoplasms
Protein-Tyrosine Kinases
Therapeutics
Signal transduction
Signal Transduction
Carcinogenesis
Ligands
Molecules

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

これを引用

Epidermal growth factor receptor in relation to tumor development : EGFR-targeted anticancer therapy. / Okamoto, Isamu.

:: FEBS Journal, 巻 277, 番号 2, 01.01.2010, p. 309-315.

研究成果: ジャーナルへの寄稿小調査

@article{57ba6b5b38bd4ea68ab2916c14f6efc5,
title = "Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy",
abstract = "The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.",
author = "Isamu Okamoto",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1742-4658.2009.07449.x",
language = "English",
volume = "277",
pages = "309--315",
journal = "FEBS Journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor in relation to tumor development

T2 - EGFR-targeted anticancer therapy

AU - Okamoto, Isamu

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.

AB - The discovery that signaling by the epidermal growth factor receptor (EGFR) plays a key role in tumorigenesis prompted efforts to target this receptor in anticancer therapy. Two different types of EGFR-targeted therapeutic agents were subsequently developed: mAbs, such as cetuximab and panitumumab, which target the extracellular domain of the receptor, thereby inhibiting ligand-dependent EGFR signal transduction; and small-molecule tyrosine kinase inhibitors, such as gefitinib and erlotinib, which target the intracellular tyrosine kinase domain of the EGFR. Furthermore, recent clinical and laboratory studies have identified molecular markers that have the potential to improve the clinical effectiveness of EGFR-targeted therapies. This minireview summarizes the emerging role of molecular profiling in guiding the clinical use of anti-EGFR therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=74549118220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549118220&partnerID=8YFLogxK

U2 - 10.1111/j.1742-4658.2009.07449.x

DO - 10.1111/j.1742-4658.2009.07449.x

M3 - Short survey

C2 - 19922468

AN - SCOPUS:74549118220

VL - 277

SP - 309

EP - 315

JO - FEBS Journal

JF - FEBS Journal

SN - 1742-464X

IS - 2

ER -